Impact Factor: 1.2

Ahead of Print

Editorial

Available online: 06/13/2024

The challenging pathway to TAVI: in memory of Alain Cribier

El arduo camino hacia el TAVI: en recuerdo de Alain Cribier

Eulogio García,a, Leire Unzué,b and Rodrigo Teijeirob

aServicio de Cardiología Intervencionista, Hospital Gregorio Marañón, Hospital Clínico San Carlos, Hospital Montepríncipe y Hospital Moncloa, Madrid, Spain

bServicio de Cardiología Intervencionista, Hospital Montepríncipe y Hospital Moncloa, Madrid, Spain

In 1998, in response to a comment on the limited durability of an aortic valvuloplasty performed during the last Madrid Interventional Cardiology (MIC) course, Alain Cribier insightfully stated: “We’ll mount a stent on the valvuloplasty balloon, attach the leaflets, and problem solved.” Four years and countless hours of work later, both at his hospital in Rouen, France, and at the animal experimentation center in Lyon, France, the recently deceased Alain Cribier (1945-2024) achieved a groundbreaking milestone.1 On April 16, 2002, he performed the world’s first surgery-free transcatheter aortic valve implantation (TAVI), prolonging the patient’s life and revolutionizing heart valve surgery. This innovation dramatically improved the quality of life of a high percentage of patients with severe aortic stenosis who were ineligible for conventional heart surgery. Since then, more than a million patients have benefited from his technological innovation.

After this pivotal first case of TAVI,1 isolated procedures were performed in selected patients in the following years, with few technical variations, and all via antegrade access. While interventional cardiologists were enthusiastic and had high expectations, critics predicted apocalyptic disasters due to alleged complications, such as vascular complications, valve instability and migration, coronary occlusion, strokes, annular and aortic rupture, paravalvular regurgitation, and concerns about the durability of the valve. In 2006, the first clinical trials (REVIVAL2 in the United States and REVIVE3 in Europe) changed the procedure strategy. The adoption of retrograde access, facilitated by the versatility of a flexible carrier catheter, considerably simplified the technique and contributed to its widespread adoption.

After a stay in Vancouver, Canada to acquire theoretical and practical training in the technique, and with Cribier’s assistance, a team of interventional cardiologists from Hospital Gregorio Marañón, Madrid, Spain successfully implanted the first 2 aortic valves via transfemoral access in Spain on April 23, 2007 (figure 1). Throughout 2007, the team contributed to the REVIVE trial, successfully treating 10 patients with transfemoral TAVI, with no perioperative mortality or major complications. This success, with contributions from other European centers, paved the way for the approval of this technology for clinical use.


Figure 1. First transcatheter aortic valve implantation performed in Spain, on April 23rd, 2007. In the photograph, from left to right, Dr. Alain Cribier, Dr. Eulogio García, and Dr. Javier Ortal.


After standardizing and defining the complications associated with the procedure,4 the randomized PARTNER clinical trials were conducted in inoperable patients and high-risk surgical patients.5,6 These trials confirmed the safety and efficacy of TAVI, establishing it as the treatment of choice for high-risk patients.7 Eventually TAVI became the preferred treatment for all patients with aortic stenosis older than 75 years.8-10

In this exciting journey, we contributed a few technical improvements, demonstrating the safety of direct implantation without prior valvuloplasty11 and improving the management of vascular access via contralateral access.12 The gradual simplification of TAVI led to its classification as a “minimally invasive procedure”. It is now available in all cath labs, with more than 1 million valves implanted in all 5 continents.13

Alain Cribier was technically elegant and efficient; meticulous, systematic, and generous in his teaching. His perseverance in the management of aortic stenosis drove him to seek a definitive solution. Bernard Guiraud-Chaumeil, former president of the French health assessment department, highlighted Cribier’s exceptional contribution to the management of valvular heart disease, stating: “Revolutionary advances in medicine must be accessible to patients as soon as possible.” Cribier’s dedication, perseverance, and ingenuity changed the history of severe aortic stenosis; his legacy will not only save thousands of lives but will also improve the clinical practice of present and future generations of interventional cardiologists.

FUNDING

None declared.

CONFLICTS OF INTEREST

None declared.

REFERENCES

1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:First human case description. Circulation. 2002;106:3006-3008.

2. Kodali SK, O'Neill WW, Moses JW, et al. Early and late (one year) outcomes following transcatheter aortic valve implantation in patients with severe aortic stenosis (from the United States REVIVAL trial). Am J Cardiol. 2011;107:1058-1064.

3. Garcia E, Pinto AG, Sarnago Cebada F, et al. Percutaneous Aortic Valve Implantation: Initial Experience in Spain. Rev Esp Cardiol. 2008;61:1210-1214.

4. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials:a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011;57:253-269.

5. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.

6. Schymik G, Heimeshoff M, Bramlage P, et al. A comparison of transcatheter aortic valve implantation and surgical aortic valve replacement in 1,141 patients with severe symptomatic aortic stenosis and less than high risk. Catheter Cardiovasc Interv. 2015;86:738-744.

7. Baumgartner H, Falk V, Bax JJ, et al.;ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.

8. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.

9. Reardon MJ, Van Mieghem NM, Popma JJ, et al.;SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376:1321-1331.

10. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380:1695-1705.

11. García E, Almería C, UnzuéL, Jiménez-Quevedo P, Cuadrado A, Macaya C. Transfemoral implantation of Edwards Sapien XT aortic valve without previous valvuloplasty:Role of 2D/3D transesophageal echocardiography. Catheter Cardiovasc Interv. 2014;84:868-876.

12. García E, Martín-Hernández P, UnzuéL, Hernández-Antolín RA, Almería C, Cuadrado A. Usefulness of placing a wire from the contralateral femoral artery to improve the percutaneous treatment of vascular complications in TAVI. Rev Esp Cardiol. 2014;67:410-412.

13. Akodad M, Lefèvre T. TAVI:Simplification Is the Ultimate Sophistication. Front Cardiovasc Med. 2018;5:96.

* Corresponding author.

E-mail address: Ejgarcia1@telefonica.net (E. García).

  @Eulogio43942113

Special articles

Recic Uk 23 075 F2

Original articles

Recic Uk 23 065 F3

Editorials


Original articles

Recic Uk 23 072 F3
Recic Uk 23 099 F3
Recic Uk 23 044 F1

Editorials

Recic 23 092 F2

Review Articles

Recic Uk 23 077 F1

Debate

Debate: Ablation vs lithotripsy in calcified coronary lesions

Recic 23 102 F1
Recic 23 100 F1

Review Articles

Recic Uk 23 128 F1

Scientific letters

Images in cardiology

Recic Uk 23 048 F1

Original articles